Shares of Stoke Therapeutics, Inc. (NASDAQ: STOK) rose sharply in today’s pre-market trading after the company announced Phase 1/2a data supporting the potential for STK-001 in Dravet syndrome.
Stoke Therapeutics shares jumped 69.7% to $11.03 in pre-market trading
Here are some other stocks moving in pre-market trading.
Gainers
Check-Cap Ltd. (NASDAQ: CHEK) shares gained 38.3% to $2.67 in pre-market trading. Nobul AI Corp entered into business combination agreement with Check-Cap.
C3is Inc. (NASDAQ: CISS) rose 35.2% to $0.0476 in pre-market trading. C3is is expected to release its fourth quarter financial results before the opening bell on March 26, 2024.
OpGen, Inc. (NASDAQ: OPGN) gained 30.4% to $0.6196 in pre-market trading after the company announced David Lazar will invest $3 million in preferred stock and take over as CEO.
Mesoblast Limited (NASDAQ: MESO) gained 23.2% to $2.71 in pre-market trading. Mesoblast was notified by the U.S. FDA that available clinical data from Phase 3 trial appear sufficient to support BLA submission for Remestemcel-L in children with steroid-refractory ...
Related tickers: IVVD, BREA, WPRT, SXTP, VIVK, INTJ, APCX, CISS, DADA, EGOX, CHEK, OPGN, MESO, GDS, STOK, NBSE, DNUT, TIVC, BZFD, GWAV.
Read Full Article
